Idelalisib and rituximab are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.
- Idelalisib (Zydelig®) is a phosphoinositide 3-kinase inhibitor and is indicated for the treatment of chronic lymphocytic B-cell leukemia and non-Hodgkin lymphoma.
- Rituximab (MabThera®, Truxima®, Rituxan®) is a monoclonal antibody and is indicated for the treatment of chronic lymphocytic B-cell leukemia and non-Hodgkin lymphoma.
